Stryker Co. (NYSE:SYK) Holdings Raised by Geode Capital Management LLC

Geode Capital Management LLC raised its position in Stryker Co. (NYSE:SYK - Free Report) by 2.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,905,126 shares of the medical technology company's stock after acquiring an additional 165,490 shares during the quarter. Geode Capital Management LLC owned approximately 1.81% of Stryker worth $2,484,893,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in SYK. Burke & Herbert Bank & Trust Co. purchased a new position in Stryker in the second quarter valued at $340,000. Wealth Enhancement Advisory Services LLC grew its stake in shares of Stryker by 78.9% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 133,020 shares of the medical technology company's stock worth $45,260,000 after purchasing an additional 58,673 shares in the last quarter. ORG Partners LLC increased its holdings in shares of Stryker by 788.2% in the 2nd quarter. ORG Partners LLC now owns 302 shares of the medical technology company's stock valued at $102,000 after acquiring an additional 268 shares during the last quarter. Addenda Capital Inc. boosted its holdings in shares of Stryker by 11.6% in the 2nd quarter. Addenda Capital Inc. now owns 18,699 shares of the medical technology company's stock valued at $6,375,000 after buying an additional 1,950 shares in the last quarter. Finally, GPS Wealth Strategies Group LLC grew its position in shares of Stryker by 32.2% in the 2nd quarter. GPS Wealth Strategies Group LLC now owns 484 shares of the medical technology company's stock valued at $165,000 after buying an additional 118 shares during the last quarter. Institutional investors and hedge funds own 77.09% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the stock. Wells Fargo & Company upped their price objective on shares of Stryker from $381.00 to $405.00 and gave the company an "overweight" rating in a research note on Wednesday, October 30th. Wolfe Research initiated coverage on shares of Stryker in a research report on Tuesday, September 10th. They set an "outperform" rating and a $405.00 price objective on the stock. UBS Group increased their target price on shares of Stryker from $366.00 to $370.00 and gave the stock a "neutral" rating in a research note on Wednesday, October 30th. JPMorgan Chase & Co. upped their price objective on Stryker from $375.00 to $420.00 and gave the company an "overweight" rating in a research note on Wednesday, October 30th. Finally, Citigroup boosted their target price on Stryker from $406.00 to $411.00 and gave the company a "buy" rating in a report on Thursday, October 31st. Four analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company's stock. Based on data from MarketBeat, Stryker presently has a consensus rating of "Moderate Buy" and an average target price of $398.40.

Stryker Trading Up 0.4 %

NYSE SYK traded up $1.57 during mid-day trading on Tuesday, reaching $382.68. 1,276,871 shares of the stock were exchanged, compared to its average volume of 1,261,261. The business's fifty day simple moving average is $371.49 and its 200 day simple moving average is $354.02. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.22 and a current ratio of 1.91. The stock has a market capitalization of $145.89 billion, a PE ratio of 41.02, a PEG ratio of 2.90 and a beta of 0.94. Stryker Co. has a 1-year low of $285.79 and a 1-year high of $398.20.

Stryker (NYSE:SYK - Get Free Report) last released its earnings results on Tuesday, October 29th. The medical technology company reported $2.87 EPS for the quarter, beating the consensus estimate of $2.77 by $0.10. The firm had revenue of $5.49 billion during the quarter, compared to analyst estimates of $5.37 billion. Stryker had a return on equity of 23.07% and a net margin of 16.34%. The business's quarterly revenue was up 11.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.46 earnings per share. On average, research analysts anticipate that Stryker Co. will post 12.06 earnings per share for the current fiscal year.

Stryker Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Tuesday, December 31st will be given a $0.84 dividend. This is a positive change from Stryker's previous quarterly dividend of $0.80. This represents a $3.36 annualized dividend and a dividend yield of 0.88%. Stryker's dividend payout ratio (DPR) is 34.30%.

Insider Buying and Selling at Stryker

In other Stryker news, VP M Kathryn Fink sold 2,121 shares of the business's stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $370.00, for a total transaction of $784,770.00. Following the transaction, the vice president now owns 10,042 shares in the company, valued at $3,715,540. The trade was a 17.44 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Kevin Lobo sold 57,313 shares of Stryker stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $368.70, for a total transaction of $21,131,303.10. Following the sale, the chief executive officer now owns 100,027 shares in the company, valued at $36,879,954.90. This represents a 36.43 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 66,781 shares of company stock valued at $24,612,275. Company insiders own 5.50% of the company's stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.